Galectin Therapeutics Inc
GALT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001133416
In the last 90 days, Galectin Therapeutics Inc insiders filed 0 open-market purchases and 1 sale; 98 institutions reported holding it in 13F filings for Q2 2026, worth $72.2M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Galectin Therapeutics Inc changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Of which not filed for Q4 2025 | Q4 2025 | Change |
|---|---|---|---|---|
| Holders | 84 | 1 | 98 | +15 |
| Shares | 10.3M | 48.0K | 11.6M | +1.37M (+13.3%) |
| Value | $43.9M | $203.3K | $48.1M | +$4.45M (+10.2%) |
1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (25)
Institutions that held Galectin Therapeutics Inc at the end of Q4 2025 but not at the end of Q3 2025.
Sold out (10)
Institutions that held Galectin Therapeutics Inc at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Group One Trading, L.P. | 99,110 | $419.7K |
| Citadel Advisors LLC | 71,306 | $302.0K |
| Ancora Advisors, LLC | 52,380 | $221.8K |
| D.A. Davidson & Co. | 10,000 | $42.4K |
| Integrated Wealth Concepts LLC | 10,000 | $42.4K |
| Barrett & Company, Inc. | 3,834 | $16.2K |
| Hantz Financial Services, Inc. | 2,083 | $9.00K |
| Bradley & Co. Private Wealth Management, LLC | 1,000 | $4.24K |
| Salem Investment Counselors Inc | 167 | $708 |
| SRS Capital Advisors, Inc. | 52 | $220 |
Not filed for Q4 2025 yet (1)
Institutions that held Galectin Therapeutics Inc at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Synovus Financial Corp | 48,000 | $203.3K |